
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with Pharmaceutical from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/pharmaceutical/topic/194/</link>
        <description>Articles tagged with Pharmaceutical from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>J&amp;J OTC sales slipped 3% in 2012 worldwide</title>
          <description>CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year&apos;s numbers.</description>
          <link>http://www.mmm-online.com/jj-otc-sales-slipped-3-in-2012-worldwide/article/277043/</link>
          <pubDate>Tue, 22 Jan 2013 18:19:42 GMT</pubDate>
          <itunes:summary>CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year&apos;s numbers.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Branded drug spend up, but slower growth ahead</title>
          <description>Last year, a wave of new products brought the industry succor as it awaits the full impact of the patent cliff on blockbuster brands. But companies should brace for contraction.</description>
          <link>http://www.mmm-online.com/branded-drug-spend-up-but-slower-growth-ahead/article/235233/</link>
          <pubDate>Thu, 05 Apr 2012 13:00:00 GMT</pubDate>
          <itunes:summary>Last year, a wave of new products brought the industry succor as it awaits the full impact of the patent cliff on blockbuster brands. But companies should brace for contraction.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Company news: GlaxoSmithKline, AstraZeneca, Nature Publishing</title>
          <description>GlaxoSmithKline is building its first new UK factory in almost 40 years, the firm said, spurring jobs while breaking new ground at some of its current locations.</description>
          <link>http://www.mmm-online.com/company-news-glaxosmithkline-astrazeneca-nature-publishing/article/233198/</link>
          <pubDate>Thu, 22 Mar 2012 15:52:20 GMT</pubDate>
          <itunes:summary>GlaxoSmithKline is building its first new UK factory in almost 40 years, the firm said, spurring jobs while breaking new ground at some of its current locations.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>As brand revenue shrinks, so does brand promotion</title>
          <description>Branded drug sales declined 0.7% to $229 billion last year, according to IMS Health, and that&apos;s having an impact on promotional spend.</description>
          <link>http://www.mmm-online.com/as-brand-revenue-shrinks-so-does-brand-promotion/article/201146/</link>
          <pubDate>Fri, 22 Apr 2011 15:44:00 GMT</pubDate>
          <itunes:summary>Branded drug sales declined 0.7% to $229 billion last year, according to IMS Health, and that&apos;s having an impact on promotional spend.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Which Pfizer brands could stay, go in a sell-off</title>
          <description>Pfizer may be headed toward a major restructuring that could include the sale of some of its most enduring brands, an analyst says.</description>
          <link>http://www.mmm-online.com/which-pfizer-brands-could-stay-go-in-a-sell-off/article/198422/</link>
          <pubDate>Tue, 15 Mar 2011 21:39:48 GMT</pubDate>
          <itunes:summary>Pfizer may be headed toward a major restructuring that could include the sale of some of its most enduring brands, an analyst says.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Abbott&apos;s pharma unit retools as US boss retires</title>
          <description>Abbott Labs&apos; US pharmaceuticals business is undergoing some hefty changes: about 1,500 layoffs, a merger with the international division and the retirement of its SVP.</description>
          <link>http://www.mmm-online.com/abbotts-pharma-unit-retools-as-us-boss-retires/article/197015/</link>
          <pubDate>Thu, 24 Feb 2011 19:58:22 GMT</pubDate>
          <itunes:summary>Abbott Labs&apos; US pharmaceuticals business is undergoing some hefty changes: about 1,500 layoffs, a merger with the international division and the retirement of its SVP.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Federal appeals court overturns Vermont data ban</title>
          <description>A federal appeals court on Tuesday reversed a district court ruling that limited the use of prescriber-identifiable data in Vermont, signaling a victory for plaintiffs IMS Health, SDI and Wolters Kluwer Health.</description>
          <link>http://www.mmm-online.com/federal-appeals-court-overturns-vermont-data-ban/article/191529/</link>
          <pubDate>Wed, 24 Nov 2010 14:00:00 GMT</pubDate>
          <itunes:summary>A federal appeals court on Tuesday reversed a district court ruling that limited the use of prescriber-identifiable data in Vermont, signaling a victory for plaintiffs IMS Health, SDI and Wolters Kluwer Health.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Roche details job cuts, passes Tamiflu to contract sales org</title>
          <description>Roche detailed its &quot;operational excellence&quot; cost-cutting program in a statement today, which includes a reduction of 2,650 pharmaceutical sales and marketing jobs. In total, 6,300 jobs will be affected by the restructuring.</description>
          <link>http://www.mmm-online.com/roche-details-job-cuts-passes-tamiflu-to-contract-sales-org/article/191077/</link>
          <pubDate>Wed, 17 Nov 2010 21:05:12 GMT</pubDate>
          <itunes:summary>Roche detailed its &quot;operational excellence&quot; cost-cutting program in a statement today, which includes a reduction of 2,650 pharmaceutical sales and marketing jobs. In total, 6,300 jobs will be affected by the restructuring.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Few patients look to pharma sites for health info, survey says</title>
          <description>Patients taking a medication and looking online for health information tend to avoid pharmaceutical company sites, according to an online survey conducted by Accenture.</description>
          <link>http://www.mmm-online.com/few-patients-look-to-pharma-sites-for-health-info-survey-says/article/190956/</link>
          <pubDate>Tue, 16 Nov 2010 18:23:42 GMT</pubDate>
          <itunes:summary>Patients taking a medication and looking online for health information tend to avoid pharmaceutical company sites, according to an online survey conducted by Accenture.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>DDMAC regulatory letters could double in 2010</title>
          <description>New Year&apos;s Eve is five months away, but FDA letter-writers have already been prolific in 2010 on themes of risk omission, inflated efficacy claims, and unfair balance presentation as seen in promotional materials targeting physicians and consumers.</description>
          <link>http://www.mmm-online.com/ddmac-regulatory-letters-could-double-in-2010/article/175154/</link>
          <pubDate>Thu, 22 Jul 2010 16:41:27 GMT</pubDate>
          <itunes:summary>New Year&apos;s Eve is five months away, but FDA letter-writers have already been prolific in 2010 on themes of risk omission, inflated efficacy claims, and unfair balance presentation as seen in promotional materials targeting physicians and consumers.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  